These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 21593750)
1. Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Kaul S; Diamond GA Clin Pharmacol Ther; 2011 Jun; 89(6):773-6. PubMed ID: 21593750 [No Abstract] [Full Text] [Related]
5. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Dahabreh IJ; Economopoulos K Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649 [TBL] [Abstract][Full Text] [Related]
6. The rough road for rosiglitazone. Goldfine AB Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes? Vaccaro O; Riccardi G Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715 [No Abstract] [Full Text] [Related]
10. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563 [TBL] [Abstract][Full Text] [Related]
12. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323 [TBL] [Abstract][Full Text] [Related]
13. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Hernandez AV; Walker E; Ioannidis JP; Kattan MW Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493 [TBL] [Abstract][Full Text] [Related]
14. Comment: Thiazolidinediones in type 2 diabetes: a cardiology perspective. Musini VM; Bassett KL; Tejani AM Ann Pharmacother; 2009 Feb; 43(2):391-2; author reply 392-3. PubMed ID: 19193598 [No Abstract] [Full Text] [Related]
15. Rosiglitazone and cardiovascular disease: a cardiologist's perspective. Marx N Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439 [No Abstract] [Full Text] [Related]
16. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis. Tan A; Cao Y; Xia N; Mo Z; Gao F Eur J Intern Med; 2010 Oct; 21(5):398-403. PubMed ID: 20816593 [TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
18. Controversy over the cardiovascular effects of thiazolidinediones. Kapoor JR Am J Med; 2008 Apr; 121(4):e9. PubMed ID: 18374677 [No Abstract] [Full Text] [Related]
19. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart. Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888 [No Abstract] [Full Text] [Related]
20. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. George J; Hannah S; Lang CC Cardiovasc Ther; 2009; 27(2):83-8. PubMed ID: 19426244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]